Tuberculosis Clinical Trial
This trial aims to increase the wellbeing of tuberculosis patients and their adherence to
medication in Chisinau, The Republic of Moldova. The design is an individually randomised
controlled trial (RCT) and will involve 400 TB patients during their 'continuation phase' of
treatment. The trial will have two arms; 200 patients will form the control group and
receive the standard provision of Directly Observed Treatment (DOT) and 200 will receive
Virtually Observed Treatment (VOT).
VOT differs from DOT in that the daily observation of patients taking their medication will
be observed via internet video messages rather than in-person. Based on a small sample of
patient interviews we think that for some patients DOT may be a hindrance rather than a
help. VOT allows patients to take their treatment in the comfort of their home and means
they don't have to travel to their polyclinic every day.
There will be a central VOT observation centre where VOT observers will view and respond to
video messages sent in by patients in the VOT arm. The messages will be sent via an M-Health
app. The VOT observers will also respond to the patients by sending feedback to the
patients. The trial duration will depend on the recruitment rate of eligible patients but is
expected to take 16 months.
Status | Not yet recruiting |
Enrollment | 400 |
Est. completion date | March 2017 |
Est. primary completion date | February 2017 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Consent to being part of the trial 2. Live in Chisinau and no plans to move away from Chisinau during the four months 3. Aged 18 or over 4. At least four months of care remaining Exclusion Criteria: 1. Having MDR-TB 2. Homeless 3. Is not homeless 4. Suffer from alcoholism or drug misuse 5. In prison 6. Has a treatment regimen with injections |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
The Behavioural Insights Team |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Adherence to medication | Number of days per two week period that each patient fails to adhere to treatment, continuous. Panel data collected from TB-01 record sheets for duration of patient continuation phase of treatment - on average 5 months | 2 weeks | No |
Secondary | Adherence 80% | Proportion of patients having more than 80% of scheduled medication sessions per two week period (binary). Panel data collected for duration of patient continuation phase of treatment - on average 5 months | 2 weeks | No |
Secondary | Patient wellbeing | Self reported using a short form version (5 questions) of the WEMWBS questionnaire for measuring mental wellbeing was developed by researchers at Warwick and Edinburgh Universities | Collected at 4 months | No |
Secondary | Patient satisfaction | Binary variable equal to 1 if a patient gives a positive response about their treatment on a likert scale (questionnaire, self-reported) | Collected at 4 months | No |
Secondary | Travel and time cost of treatment borne by patient, self reported. | Total travel time and cost over 4 months (derived from questionnaire, self-reported) | Collected at 4 months | No |
Secondary | Employment, self reported | Binary variable equal to 1 if patient currently does any work for pay or profit (questionnaire, self-reported) | Collected at 4 months | No |
Secondary | Treatment success | Binary variable equal to 1 if treatment recorded a success on TB-01 patient record at 4 months | Collected at 4 months | No |
Secondary | Body mass index (BMI) | Body mass index (BMI), measured at 4 months | Collected at 4 months | No |
Secondary | Side effects reported during treatment | Binary variable equal to 1 if patient reported any side effects during treatment (questionnaire, self-reported) | Collected at 4 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05738681 -
Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial
|
Phase 2/Phase 3 | |
Recruiting |
NCT05526885 -
Tuberculosis Diagnostic Trial of CAD4TB Screening Alone Compared to CAD4TB Screening Combined With a CRP Triage Test, Both Followed by Confirmatory Xpert MTB/RIF Ultra in Communities of Lesotho and South Africa
|
N/A | |
Completed |
NCT04369326 -
Community Initiated Preventive Therapy for TB
|
N/A | |
Recruiting |
NCT04568967 -
TB-CAPT EXULTANT - HIV
|
N/A | |
Completed |
NCT02337270 -
Phase 1 Clinical Trial of the Safety and Immunogenicity of an Adenovirus-based TB Vaccine Administered by Aerosol
|
Phase 1 | |
Not yet recruiting |
NCT06253715 -
Shortened Regimen for Drug-susceptible TB in Children
|
Phase 3 | |
Recruiting |
NCT04271397 -
Immunological Biomarkers in Tuberculosis Management
|
N/A | |
Withdrawn |
NCT03639038 -
Tuberculosis Diagnosis by Flow Cytometry
|
||
Completed |
NCT03199313 -
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid
|
Phase 1 | |
Recruiting |
NCT04975178 -
Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa
|
Phase 3 | |
Completed |
NCT04463680 -
Rifampin and the Contraceptive Implant
|
Phase 4 | |
Completed |
NCT03973970 -
Assessing the Ability of the T-SPOT®.TB Test (IQ)
|
||
Recruiting |
NCT04230395 -
Alcohol Reduction Among People With TB and HIV in India
|
N/A | |
Completed |
NCT04874948 -
Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment
|
Phase 1 | |
Active, not recruiting |
NCT02906007 -
Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis, Living With or Without HIV
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05917210 -
Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda
|
N/A | |
Not yet recruiting |
NCT06017843 -
Impact Evaluation of Use of MATCH AI Predictive Modelling for Identification of Hotspots for TB Active Case Finding
|
N/A | |
Not yet recruiting |
NCT05845112 -
Start Taking Action For TB Diagnosis
|
||
Active, not recruiting |
NCT02715271 -
Study of TB Lesions Obtained in Therapeutical Surgery
|
||
Completed |
NCT02781909 -
Potential Efficacy and Safety of Using Adjunctive Ibuprofen for XDR-TB Tuberculosis
|
Phase 2 |